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Introduction
Atopic dermatitis is a chronic eczematous skin disease accom-
panied by severe itch, episodes which are frequently repeated
(1,2). In most cases, onset of the disease is observed in infants
and is considered to be dependent on both genetic and envi-
ronmental factors. Elevated serum IgE levels are also a char-
acteristic feature in many patients (3,4). Itchiness is the most
important problem for atopic patients and scratching worsens
the dermatitis itself. Patients suffering from atopic dermatitis,
especially adult patients with severe symptoms, have been
increasing in Japan, and inappropriate usage of topical
glucocorticoids has been emphasized as one of its main
causes (1).
Topical glucocorticoids are important and effective remedies
for treatment of atopic dermatitis. It is well known, however,
that prolonged use of high dose glucocorticoids frequently
causes a variety of adverse effects (5,6). Recently, tacrolimus,
an immunosuppressant, has been introduced for treating of
atopic dermatitis, but its efficacy is less than that of glucocor-
ticoids (7,8). In contrast to these drugs, which are supposedly
targeted at disease mechanisms, Kampo medicines essentially
aim to correct the patient’s constitution, hoping to bring about
a cure of the disease secondarily (9,10). As Kampo medicines
usually contain many different constituents, it is sometimes
difficult to identify the active components and to elucidate the
mechanism of their actions. However, the approach of Kampo
medicines seems to be beneficial for treating of chronic
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medicines have been tried for treating atopic dermatitis, but the
scientific evidence on their efficacy is rarely available (11,12).
We have established an allergic dermatitis model in NC/Nga
mice by repeated local exposure of mite antigen (13). The
dermatitis possesses some characteristic features observed in
atopic dermatitis patients, such as eczematous skin lesion with
inflammatory cell accumulation, a Th1/Th2 balance skewed to
Th2 and elevated serum IgE levels. The Th1/Th2 imbalance
has been considered to be an important feature of atopic
disease (14,15).
In this study, we examined the effects of four Kampo
medicines, Juzen-taiho-to, Hochu-ekki-to, Shofu-san and Oren-
gedoku-to, on the mite antigen-induced dermatitis in NC/Nga
mice to obtain basic information about their usefulness in the
treatment of atopic dermatitis.
Materials and Methods
Mice
Female NC/Nga mice, 6 weeks of age, were obtained from
Japan SLC (Hamamatsu, Japan) and maintained for 2 weeks
before organizing the experiment. They were housed in an air-
conditioned animal room at a temperature of 22   1 C
and humidity of 60   5%, and fed a laboratory diet and water
ad libitum. Experiments were undertaken following the guide-
lines for the care and use of experimental animals of the
Japanese Association for Laboratory Animal Science (16).
Drugs
Dried extracts of Juzen-taiho-to (TJ-48), Hochu-ekki-to 
(TJ-41), Shofu-san (TJ-22) and Oren-gedoku-to (TJ-15) were
provided by Tsumura & Co. (Tokyo, Japan). Constituent
herbal medicines, their origins and their amounts per day are
indicated in Table 1. The dried amount of extract obtained
from each set of herbal medicines was roughly 5 g for Juzen-
taiho-to, 5 g for Hochu-ekki-to, 4 g for Shofu-san and 1.5 g for
Oren-gedoku-to. The quality of the extracts was checked by
examining the quantity of key compounds using HPLC. The
HPLC profile of Juzen-taiho-to is indicated in Fig. 1 as an
example. The extracts were dissolved in distilled water and
given to mice orally at doses of 100 and 300 mg/kg once a day
throughout the experiment. Prednisolone (phosphate, Banyu,
Tokyo, Japan) obtained commercially was used as a reference
drug. It was dissolved in distilled water and given orally at a
dose of 3 mg/kg once a day throughout the experiment. The
doses of Kampo medicines and prednisolone were decided
according to our preliminary experiments.
Mite Antigen
Dermatophagoides farinae crude extract (mite antigen,
lyophilized, Torii, Tokyo, Japan) was used as an antigen (17).
Mite antigen was dissolved in phosphate buffered saline (PBS)
containing 0.5% Tween 20.
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Table 1. Examination of Kampo medicines and their constituents
Constituent Origin Family Amount (g)
Juzen-taiho-to (TJ-48)
Astragali Radix Astragalus  Leguminosae 3
membranaceus
Glycyrrhizae Radix Glycyrrhiza glabra Leguminosae 1.5
Cinnamomi Cortex Cinnamomum cassia Lauraceae 3
Rehmanniae Radix Rehmannia glutinosa Scrophulariaceae 3
Paeoniae Radix Paeonia lactiflora Paeoniaceae 3
Cnidii Rhizoma Cnidium officinale Umbelliferae 3
Atractylodis Lanceae  Atractylodes lancea Compositae 3
Rhizoma
Angelicae Radix Angelica acutiloba Umbelliferae 3
Ginseng Radix Panax ginseng Araliaceae 3
Hoelen Poria cocos Polyporaceae 3
Hochu-ekki-to (TJ-41)
Astragali Radix Astragalus  Leguminosae 4
membranaceus
Glycyrrhizae Radix Glycyrrhiza glabra Leguminosae 1.5
Bupleuri Radix Bupleurum falcatum Umbelliferae 2
Zingiberis Rhizoma Zingiber officinale Zingiberaceae 0.5
Cimicifugae Rhizoma Cimicifuga simplex Ranunculaceae 1
Atractylodis Lanceae  Atractylodes lancea Compositae 4
Rhizoma
Zizyphi Fructus Zizyphus jujuba Rhamnaceae 2
Aurantii Nobilis  Citrus unshiu Rutaceae 2
Pericarpium
Angelicae Radix Angelica acutiloba Umbelliferae 3
Ginseng Radix Panax ginseng Araliaceae 4
Shofu-san (TJ-22)
Glycyrrhizae Radix Glycyrrhiza glabra Leguminosae 1
Sophorae Radix Sophora flavescens Leguminosae 1
Schizonepetae Spica Schizonepeta  Labiatae 1
tenuifolia
Arctii Fructus Arctium lappa Compositae 2
Sesami Semen Sesamum indicum Pedaliaceae 1.5
Rehmanniae Radix Rehmannia glutinosa Scrophulariaceae 3
Gypsum Fibrosum 3
Cicadae Periostracum Cryptotympana  Cicadidae 1
pustulata
Atractylodis Lanceae  Atractylodes lancea Compositae 2
Rhizoma
Anemarrhenae  Anemarrhena  Liliaceae 1.5
Rhizoma asphodeloides
Angelicae Radix Angelica acutiloba Umbelliferae 3
Ledebouriellae Radix Ledebouriella  Umbelliferae 2
seseloides
Akebiae Caulis Akebia quinata Lardizabalaceae 2
Oren-gedoku-to (TJ-15)
Scutellariae Radix Scutellaria baicalensis Labiatae 3
Phellodendri Cortex Phellodendron  Rutaceae 1.5
amurense
Coptidis Rhizoma Coptis japonica Ranunculaceae 2
Gardeniae Fructus Gardenia jasminoides Rubiaceae 2
The amount for each constituent indicates that for 1 day.eCAM 2005;2(2) 193
Induction of Dermatitis in the Mouse Ear
Both surfaces of mouse ear lobes were stripped three times
using surgical tape (W129, Nichiban, Tokyo, Japan). One hour
after the tape stripping, 25  l of 10 mg/ml mite antigen solu-
tion was painted onto each surface of both ear lobes. Tape
stripping and mite antigen painting was repeated five times at
7-day intervals and ear thickness was measured using a dial
thickness gauge (R12-1A, Ozaki, Tokyo, Japan) immediately
before each tape stripping, and 1, 4 and 24 h after each mite
antigen application. In control mice, carrier solution only was
painted instead of mite antigen solution. Results were
expressed as increased ear thickness after subtracting the value
obtained before the first tape stripping.
Blood samples were obtained 24 h after each antigen
application and used for measuring serum IgE. Cervical lymph
nodes and ears were removed for evaluating cytokine mRNA
expression 4 h after the fifth antigen application. Ears for the
histological observation were separated 24 h after the fifth
antigen application.
Measurement of Serum IgE
Total serum IgE was measured using enzyme-linked immuno-
sorbent assay. In brief, 100  l of 5  g/ml rat anti-mouse IgE
heavy chain (Serotec, Oxford, UK) in PBS was placed in each
well of an immunoplate (Nunc Immunoplate I, 96-well, Nalge
Nunc International, Rochester, NY, USA) and the plate was
kept overnight at 4 C. After washing the wells with PBS
containing 0.1% Tween 20 (washing buffer) five times, 200  l
of PBS containing 1% bovine serum albumin (BSA–PBS) was
placed in each well. After 1 h at room temperature, the wells
were washed five times with washing buffer and 100  l of
serum samples diluted 30-fold with BSA–PBS were placed in
the wells. After further incubation for 1 h at room temperature,
wells were again washed five times with washing buffer, and
then 100  l of peroxide-labeled polyclonal anti-mouse IgE
goat IgG antibody (Nordic Immunological Laboratory,
Tilburg, Netherlands) diluted 5000-fold with washing buffer
was added to the wells and the plate was kept for 1 h at room
temperature. After washing five times with washing buffer,
enzyme reaction was initiated by adding 100  l of substrate
solution (containing 0.1 M citric acid, 0.2 M Na2HPO4,
o-phenylene diamine and H2O2) and the plate was kept for
30 min at room temperature in a dark place. The reaction was
terminated by adding 50  l of 2 M H2SO4 to each well, and
absorbance at 492 nm was measured immediately using an
immunoreader (Titertek Multiscan MCC/340, Dainippon,
Osaka, Japan). Standard curve was prepared using monoclonal
Figure 1. HPLC profile of Juzen-taiho-to. Ingredients of Juzen-taiho-to (1.0 g of preparation) were extracted with 20 ml of methanol for 30 min under sonication
and 30  l of the extract was used for the HPLC analysis. Column, TSK-GEL 80TS (4.6 mm   250mm, Tosoh, Japan); pump, LC-10ADVP (Shimadzu, Japan);
detector, SPD-M10AVP (Shimadzu). Mobile phase: (A) 50 mM AcOH–AcONH4 buffer, (B) CH3CN, from 90% A   10% B to 100% B in 60 min (linear gradient).
Column temperature, 40 C; flow rate, 1.0 ml/min; wavelength range, 200–400 nm.anti-DNP IgE (Sigma, St Louis, MO, USA) diluted with
BSA–PBS.
Detection of Cytokine mRNA
Expression of interleukin-4 (IL-4) and interferon-  (IFN- )
mRNA in cervical lymph nodes and ears were examined.
Excised lymph nodes and ears were homogenized in Isogen
(Nippon Gene, Tokyo, Japan) using HG 30 Homogenizer
(Hitachi, Tokyo, Japan). One milliliter of homogenate was
mixed with 200  l of chloroform (Nacalai Tesque, Kyoto,
Japan) vigorously, and centrifuged at 13 000 r.p.m. for 15 min
at 4 C using a microcentrifuge (Laboratory Centrifuge 1900,
Kubota Co., Tokyo, Japan). The aqueous phase was separated
and RNA in the phase was precipitated by mixing 0.5 ml of 
2-propanol (Nacalai Tesque). The precipitate was washed with
75% ethanol (Nacalai Tesque) and dried, and then dissolved in
diethyl pyrocarbonate (DEPC)-treated water (Nacalai Tesque).
The total RNA content was calculated based on the absorbance
at 260 nm and the quality was confirmed by electrophoresis.
Reverse transcriptase–polymerase chain reaction (RT–PCR)
was employed for the detection of mRNA. A mixture of 11  l
containing 1  g RNA, DEPC-treated water and random primer
(GIBCO BRL, Grand Island, NY, USA) was heated at 70 C for
10 min and then mixed with 4  l of 5  First Strand Buffer
(GIBCO), 1   l of 10 mM deoxynucleoside triphosphate
(dNTP, GIBCO) and 2  l of 0.1 M dithiothreitol (GIBCO).
After 5 min at 25 C, 1  l of reverse transcriptase (Superscript
II, GIBCO) was added and RT, at 25 C for 10 min, 42 C
for 50 min and then 70 C for 15 min, was performed on 
Trio-Thermoblock (Biometra, Goettingen, Germany). Then,
cDNA at a volume of 1  l was mixed with 100 mM Tris–HCl
(pH 8.3), 500 mM KCl, 1.5 mM MgCl2, 0.01% gelatin, 10 mM
dNTP, 5 U/ml ampliTaq DNA polymerase (TaKaRa Taq,Takara,
Kyoto, Japan) and 1  M primers (Stratagene, La Jolla, CA, USA)
(Table 2) and PCR (denaturation at 94 C for 1.5 min, annealing
at 62 C for 1.5 min and extension at 72 C for 1.5 min, 35 cycles)
was performed on Trio-Thermoblock. Products were elec-
trophoresed on 2% agarose gel containing ethidium bromide.
The bands were recorded by Polaroid camera (Polaroid 665
film, Nippon Polaroid, Tokyo, Japan) and densitometrically
scanned for semiquantitative evaluation. Results were normal-
ized by  -actin expression.
Histopathological Observation
Excised ear lobes were fixed with 10% neutral formalin,
embedded in paraffin, and thin, 5  m, sections were prepared.
The skin sections were stained with hematoxylin and eosin,
and observed.
Statistics
Results of ear swelling and serum IgE levels were expressed as
the means   SEM. Statistical evaluation of data was per-
formed using InStat Program (GraphPad Software, San Diego,
CA, USA). Comparison of data among Kampo medicine-
treated and control groups was performed using Dunnett’s
or Dunn’s multiple comparison test after confirming the vari-
ance of data by Bartlet’s test. Comparison of data between
prednisolone-treated and control groups was performed by
Student’s or Welch’s t-test based on the variance of data exam-
ined by F-test. When the P value was  0.05 the difference was
considered to be significant.
Results
Ear Swelling Inhibited by Varied Doses of Kampo and
Prednisolone
Results of ear swelling are shown in Fig. 2. After the fourth
and fifth mite-antigen exposure, an apparent biphasic ear
swelling was induced. Daily administration of Juzen-taiho-to
at a dose of 100 mg/kg inhibited the swelling, and a tendency
of inhibition was observed at a dose of 300 mg/kg. Hochu-
ekki-to at a dose of 300 mg/kg strongly inhibited the swelling
and at a dose of 100 mg/kg showed a tendency of inhibition. In
the case of Shofu-san, although an apparent inhibition of the
ear swelling was induced at a dose of 300 mg/kg, no effect was
observed at a dose of 100 mg/kg. Oren-gedoku-to strongly
inhibited the ear swelling at both doses of 100 and 300 mg/kg.
Prednisolone at a dose of 3 mg/kg strongly inhibited the
swelling in all four experiments.
Changes in the Serum IgE Levels
Resulting changes in serum IgE levels are shown in Fig. 3.
Apparent elevation of serum IgE was observed after the third
or fourth mite antigen exposure. Juzen-taiho-to and Hochu-
ekki-to significantly depressed the elevation, whereas Shofu-
san and Oren-gedoku-to failed to affect the serum IgE levels.
Prednisolone inhibited the elevation of serum IgE levels in
only one of four experiments. In three of four experiments, IgE
levels increased in the no antigen group.
Cytokine mRNA Expression
IL-4 and IFN-  mRNA expression in cervical lymph nodes
and ears at 4 h after the fifth antigen exposure was examined.
Results are shown in Fig. 4. Under the present experimental
conditions, IL-4 mRNA expression was minimal or undetect-
able in both cervical lymph nodes and ears of non-stimulated
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Table 2. Primers employed for detecting cytokine mRNA
Primer (product size) Sequence
 -Actin (245 bp)
Sense 5  GTG GGC CGC TAG GCA CCA 3 
Antisense 5  CGG TTG GCC TTA GGG TTC AGG GGG G 3 
IL-4 (279 bp)
Sense 5 ACG GAG ATG GAT GTG CCA AAC GTC 3 
Antisense 5  CGA GTA ATC CAT TTG CAT GAT GC 3 
IFN-  (405 bp)
Sense 5  TAC TGC CAC GGC ACA GTC ATT GAA 3 
Antisense 5  GCA GCG ACT CCT TTT CCG CTT CCT 3 eCAM 2005;2(2) 195
mice. After repeated exposure of mite antigen, however, an
apparent mRNA expression was induced in both tissues,
although the expression in ears was relatively weak (Fig. 4A).
In contrast, IFN-  mRNA expression almost comparable to
that of  -actin was detectable in mice without antigen expo-
sure. However, repeated exposure of mite antigen resulted in
an apparent depression of IFN-  mRNA expression in both
lymph nodes and ears (Fig. 4B).
Administration of all four Kampo medicines tended to inhibit
the increased expression of IL-4 mRNA in both cervical lymph
nodes and ears (Fig. 4A). In contrast, Hochu-ekki-to, Shofu-san
and Oren-gedoku-to clearly recovered the depressed expression
of IFN-  mRNA in both tissues. In the experiment with Juzen-
taiho-to, partial recovery of IFN-  mRNA expression was
observed in the ear but not in cervical lymph nodes (Fig. 4B).
Similarly, prednisolone inhibited the increase in IL-4 mRNA
expression and the decrease in IFN-  mRNA expression.
Histopathologic Data Clearly Show that Kampo
Medicines Inhibited Inflammatory Reactions
Histopathological specimens were prepared using mouse ear
lobes separated 24 h after the fifth antigen exposure. Histological
pictures are shown in Fig. 5. Repeated mite-antigen exposure
caused potent inflammatory changes, such as thickening of the
epidermis, fibrosis in the dermis and accumulation of inflam-
matory cells such as lymphocytes, eosinophils and neutro-
phils in the ear tissues (Fig. 5B). Administration of all four
Kampo medicines clearly inhibited the signs of inflam-
mation (Fig. 5C–J). Prednisolone also clearly inhibited the
inflammation (Fig. 5K).
Discussion
In the present study, we investigated the effects of four Kampo
medicines, Juzen-taiho-to, Hochu-ekki-to, Shofu-san and
Oren-gedoku-to on the atopic dermatitis model in mice, and
found that all were able to inhibit mite antigen-induced aller-
gic dermatitis in NC/Nga mice and correct the Th1/Th2 bal-
ance skewed to Th2. It is this correction of the Th1/Th2
imbalance that seems to play a role in inhibiting dermatitis.
Similar results were also obtained for prednisolone.
Kampo medicines are used primarily to correct a patient’s
constitution, with the aim of curing a disease (9,10). This
approach is in clear contrast to that of modern Western
Figure 2. Varied doses of Juzen-taiho-to, Hochu-ekki-to, Shofu-san, Oren-gedoku-to and prednisolone influence ear thickness from repeated painting with mite
antigen solution in NC/Nga mice. Ear thickness was measured immediately before, and 1, 4 and 24 h after each antigen application. Results after the first and the sec-
ond antigen applications were omitted because increased ear thickness and drug effects were negligible. Each value represents the mean   SEM of 5–8 mice. 
*P   0.05, **P   0.01 for Kampo medicine-administered groups by multiple comparison test, #P   0.05, ##P   0.01 for prednisolone-administered group by t-test.medicines, which are targeted to a symptom or an organ
directly. Although the usage of Kampo medicines is not
disease-oriented, the approach seems to be beneficial for the
treatment of chronic diseases including atopic dermatitis.
Recently, some Kampo medicines, such as Juzen-taiho-to,
Hochu-ekki-to, Shofu-san and Oren-gedoku-to have shown
promise in treating atopic dermatitis, although no literature in
English on their clinical efficacy is available at present. Juzen-
taiho-to and Hochu-ekki-to are typical prescriptions used to
aid recovery from an exhausted or weakened condition. Shofu-
san is a unique prescription used for eczematous skin diseases
accompanying pruritus. Oren-gedoku-to is prescribed to alle-
viate fever and is used for both acute and chronic phases of
various diseases. Some of the herbs involved in these prescrip-
tions, such as Glycyrrhizae Radix, Angelicae Radix, Bupleuri
Radix, Scutellariae Radix and Coptidis Rhizoma (Table 1), or
their constituents, are actually reported to exhibit modulating
activities on inflammation and immunity (18–24).
In the present study, we examined these four named Kampo
medicines using a recently established allergic dermatitis
model (13). Repeated mite antigen application coupled with
previous tape stripping produces a dermatitis possessing a
Th2-dominant background in NC/Nga mice. Elevation of
serum IgE level, and induction or potentiation of IL-4 mRNA
expression and depression of IFN-  mRNA expression in
cervical lymph nodes and ear lobes as well as potent ear
swelling were observed. The type of dermatitis induced
reflects some of the characteristic features of atopic dermatitis
and thus this model seems to be appropriate for the basic
study of atopic dermatitis. Daily oral administration of the four
Kampo medicines apparently inhibited the formation of the
ear swelling and inflammatory changes in the ear lesion. It is
interesting to note that these Kampo medicines inhibited the
increase in IL-4 mRNA expression and decrease in IFN- 
mRNA expression caused by mite-antigen exposure. Although
the inhibition of IL-4 mRNA expression was partial, recovery
of IFN-  mRNA expression was apparent, except for the
experiment with Juzen-taiho-to. In the results of Juzen-taiho-to,
IFN-  mRNA expression in mice without antigen-treatment
(non) was relatively low, and recovery of depressed expression
in prednisolone-administered mice was not apparent. Although
the reason has not yet been determined, the positive effect of
Juzen-taiho-to on the depressed expression of IFN-  mRNA
may be underestimated, similar to that of prednisolone. These
results strongly suggest that the Kampo medicines examined
in the present study are able to correct the Th1/Th2 balance
skewed to Th2, and that this activity contributes to the inhibi-
tion of the dermatitis in NC/Nga mice.
In 1999, Iijima et al. (25) reported that Juzen-taiho-to and its
component, Hoelen, shift the Th1/Th2 balance toward the
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Figure 3. Mixed results of Juzen-taiho-to, Hochu-ekki-to, Shofu-san, Oren-gedoku-to and prednisolone administration on serum total IgE levels in NC/Nga mice
repeatedly treated with mite antigen. Serum samples were obtained 24 h after each antigen application and serum IgE was quantified by enzyme-linked
immunosorbent assay. Each value indicates the mean   SEM of 5–8 mice. *P   0.05, **P   0.01 for Kampo medicine-administered groups by multiple com-
parison test; ##P   0.01 for prednisolone-administered group by t-test.eCAM 2005;2(2) 197
Th1 dominant state in ovalbumin-sensitized old BALB/c
mice. Furthermore, Matsumoto and Yamada (26) examined the
influence of oral administration of Juzen-taiho-to on the con-
canavalin A-stimulated cytokine production in mouse lympho-
cytes and reported that the ratio of produced IFN-  and IL-4 is
shifted to Th1 dominant in mesenteric lymph node cells and
Peyer’s patch cells. These reports suggest that Juzen-taiho-to
could modulate the Th1/Th2 balance and support our present
results on Juzen-taiho-to. On the other hand, Hochu-ekki-to is
also reported to regulate the Th1/Th2 balance in sensitized
mice (27). Hochu-ekki-to inhibits IgE production as well as
IL-4 production (28,29), but enhances IFN-  production
(30,31). Furthermore, not only IgE production but also spon-
taneous dermatitis in NC/Nga mice is inhibited by Hochu-
ekki-to (32). Therefore, the present results on Hochu-ekki-to
coincide well with these earlier results.
In contrast to Juzen-taiho-to and Hochu-ekki-to, modulating
effects of Shofu-san and Oren-gedoku-to on Th1 and Th2
responses, and their balance, have rarely been investigated,
although some anti-allergic and ant-inflammatory effects have
been reported (33–36). In this study, we have indicated that
these two Kampo medicines exhibit an activity which corrects
A
B
Figure 4. Application of Juzen-taiho-to, Hochu-ekki-to, Shofu-san, Oren-gedoku-to and prednisolone influence the expression of IL-4 and IFN-  mRNA in the
cervical lymph nodes and ears of NC/Nga mice treated repeatedly with mite antigen. Cervical lymph nodes and ears were obtained 4 h after the fifth antigen appli-
cation. Expression of mRNA was examined using RT–PCR. Resultant electrophoretic bands were semi-quantitatively evaluated using NIH Image software.
Experiments were repeated at least twice and a representative experiment is indicated. Results are expressed as a ratio of (A) IL-4 and (B) IFN-  to  -actin mRNA
expression. Non, no antigen; Cont, control; TJ-48, Juzen-taiho-to; TJ-41, Hochu-ekki-to; TJ-22, Shofu-san; TJ-15, Oren-gedoku-to; Pred, prednisolone; ND, not
detected.the Th1/Th2 balance skewed to Th2 in mite antigen-treated
NC/Nga mice, similar to Juzen-taiho-to and Hochu-ekki-to.
Juzen-taiho-to and Hochu-ekki-to inhibited the elevation of
serum IgE levels as well as the dermatitis in NC/Nga mice.
Actually, as mentioned above, many investigators have recog-
nized the inhibitory effect of Hochu-ekki-to on IgE production
(28,29,32). In contrast, Shofu-san and Oren-gedoku-to did not
affect IgE levels, suggesting that the correction of Th2-skewed
Th1/Th2 balance may not be a direct cause for the inhibition
of IgE production under the experimental conditions described
herein. Similarly, inhibition of IgE production by prednisolone
was inconsistent, in spite of its apparent inhibition of dermati-
tis and correction of the Th1/Th2 imbalance. NC/Nga mice
produce an atopic dermatitis-like skin lesion spontaneously
accompanied by elevated serum IgE (32,37). It has been sug-
gested that NC/Nga mice possess some genetic factors that
facilitate the induction of IgE production. The factors seem to
be independent of genetic factors that facilitate the formation
of dermatitis (38). Therefore, regulation of IgE production in
NC/Nga mice may be complicated. In contrast to the IgE
production, the four Kampo medicines examined here inhib-
ited the dermatitis and corrected the Th1/Th2 imbalance in
NC/Nga mice, suggesting that the inhibition of dermatitis may
have some correlation to the correction of Th1/Th2 imbalance.
In conclusion, the four Kampo medicines, Juzen-taiho-to,
Hochu-ekki-to, Shofu-san and Oren-gedoku-to, that have been
successfully applied in treating atopic dermatitis, inhibit the
dermatitis and inflammatory changes in the lesions and correct
the Th1/Th2 balance skewed to Th2 in mite antigen-treated
NC/Nga mice. The correcting activity of Kampo medicines for
the Th1/Th2 imbalance seems to contribute to the inhibition
of dermatitis in NC/Nga mice. This activity may also play
a role in their effectiveness for treating atopic dermatitis.
Furthermore, the mite antigen-induced allergic dermatitis
model in NC/Nga mice seems to be useful for the basic study
of atopic dermatitis.
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